NewStem For Profit
NewStem is a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University. NewStem's technology can predict patients' resistance to chemotherapy allowing for better, targeted cancer treatments and the potential to reduce resistance to chemotherapy.
Employee Number:
11-50
Investors Number:
1
Funding Status:
Seed
Headquarters:
Jerusalem, Yerushalayim, Israel
Technology:
Biomarker panels
Founded Date:
2016-09-01
Last Funding Type:
Seed
Total Funding:
$4M
Industry:
Clinical Data Management